Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,647,532 papers from all fields of science
Search
Sign In
Create Free Account
HMPL-013
Known as:
VEGFR-1/2/3 Inhibitor HMPL-013
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Benzofurans
Quinazolines
Narrower (1)
fruquintinib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
The clinical application of fruquintinib on colorectal cancer
Zhongguang Chen
,
Lili Jiang
Expert review of clinical pharmacology
2019
Corpus ID: 182950819
ABSTRACT Introduction: Anti-angiogenetic agents are currently the most commonly used drugs for the treatment of colorectal cancer…
Expand
2017
2017
A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers
Sufeng Zhou
,
Feng Shao
,
+7 authors
N. Ou
Cancer Chemotherapy and Pharmacology
2017
Corpus ID: 32597530
PurposeFruquintinib (HMPL-013) is a novel, potent, and highly selective tyrosine kinase inhibitor targeting the vascular…
Expand
2016
2016
A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with…
Junning Cao
,
Jian Zhang
,
+5 authors
Jin Li
Cancer Chemotherapy and Pharmacology
2016
Corpus ID: 8189695
PurposeFruquintinib (HMPL-013) is a novel oral small molecule compound that selectively inhibits vascular endothelial growth…
Expand
2014
2014
Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics
Yi Gu
,
Jian Wang
,
+6 authors
W. Su
Cancer Chemotherapy and Pharmacology
2014
Corpus ID: 679349
AbstractPurpose This study evaluated the preclinical pharmacokinetics (PK) and disposition of Fruquintinib (HMPL-013), a small…
Expand
2014
2014
Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy
Qiaoling Sun
,
Jinghong Zhou
,
+20 authors
Yongxin Ren
Cancer biology & therapy
2014
Corpus ID: 661259
VEGF/VEGFR signal axis has been proven to be an important target for development of novel cancer therapies. One challenging…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE